Efeito do tratamento com plasma rico em plaquetas em éguas resistentes e susceptíveis à endometrite persistente após inseminação artificial

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Comportamento de marcadores séricos de formação e reabsorção óssea após enxerto autógeno em fissura alveolar congênita: sem e com plasma rico em plaquetas

Pós-graduação em Biociências e Biotecnologia Aplicadas à Farmácia - FCFAR

Associação do plasma rico em plaquetas, novo vidro bioativo e sulfato de cálcio no tratamento de defeitos de furca classe II: estudo histológico e histométrico em cães

Pós-graduação em Odontologia - FOA

Plasma rico e plaquetas (PRP) aplicado na artroplastia total do joelho

Pós-graduação em Pesquisa e Desenvolvimento (Biotecnologia Médica) - FMB

O uso do Plasma Rico em Plaquetas (PRP) na cirurgia ortopédica

The aim of this work is to study a still little known technique in the Brazilian Veterinary Medicine, that is the use of the Platelet Rich Plasma (PRP), specifically in the small animals orthopedics, including the concept of PRP, why its use in orthopedics, its production method and application, its indications, vantages and disadvantages, and also evaluate the results achieved through the use of PRP both in Human Medicine as in Veterinary Medicine. Moreover, it aims to establish the feasibility of this technique for its use in veterinary orthopedic surgery, especially as an adjunct in fracture repair

Determinação de fatores angiogênicos e anti-angiogênicos em plasma de gestantes portadoras de pré-eclâmpsia precoce e tardia

Changes in circulating angiogenic factors have been implicated in the pathogenesis of preeclampsia. Thus, evaluation of angiogenesis agonist and antagonist factors is of greater importance to understand the mechanisms responsible for this disorder. The objective of the present study was to evaluate whether circulating angiogenic and anti-angiogenic factors may differentiate early-onset from late-onset preeclampsia. The study was conducted in 86 women with preeclampsia diagnosed in the third trimester of pregnancy. Preeclampsia was classified according to the onset of clinical manifestation in early-onset (before 34 weeks of gestation; n=31) or in late-onset (from 34 weeks of gestation on; n=55) preeclampsia. Serum was obtained from the patients in the moment of the diagnosis and assayed for placental growth factor (PlGF), vascular endothelial growth factor (VEGF), soluble Endoglin (sEng) and soluble form of vascular endothelial growth factor receptor (sVEGFR-1) determination by enzyme-linked immunosorbent assay. The results showed that early-onset preeclampsia was characterized by significant lower levels of PlGF (median 38.3 vs 123.5 pg/mL) and VEGF (median 23.1 vs 35.3 pg/mL) in serum as well as by higher serum levels of sEng (median 54.7 vs 42.1 pg/mL) and sVEGFR-1 (median 5211.0 vs 4657.6 pg/mL) compared with late-onset preeclampsia. In this study serum levels of angiogenic and anti-angiogenic factors prove useful in differentiating early-onset from late-onset preeclampsia in the third trimester of pregnancy. Therefore, these findings suggest that angiogenic factors determination may indicate that early- and late-onset preeclampsia have different pathophysiology

Estudo da produção de dextranasacarase por Leuconostoc mesenteroides FT 045 B

Pós-graduação em Ciências Biológicas (Microbiologia Aplicada) - IBRC